Solid Biosciences Gets Orphan Drug Designation for SGT-003
January 16 2024 - 8:50AM
Dow Jones News
By Chris Wack
Solid Biosciences has been granted orphan drug designation from
the U.S. Food and Drug Administration for SGT-003, the company's
next-generation Duchenne muscular dystrophy gene therapy
candidate.
The life-science company's SGT-003 received Fast Track
Designation last month.
The company said it is currently in the process of securing
approvals from the institutional review boards at the clinical
trial sites for the planned Phase 1/2 clinical trial of SGT-003 and
expects to begin patient screening shortly thereafter.
Patient dosing in the trial is expected to begin in mid-to-late
first quarter of 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 16, 2024 08:35 ET (13:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Solid Biosciences (NASDAQ:SLDB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Solid Biosciences (NASDAQ:SLDB)
Historical Stock Chart
From Apr 2023 to Apr 2024
